Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 4Breast 1

Conditions

Glioma 2Glioblastoma 2Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × azeliragon × Clear all
NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

NCT05789589 2026-03-04

ADORATION

Baptist Health South Florida

Phase 1/2 Recruiting
46 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting
48 enrolled
Breast

Cancer Related Cognitive Decline

NCT05773664 2024-09-19

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

City of Hope Medical Center

Phase 1 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡